maintenance treatment

  • April 12, 2021  

    Long-Term Survival Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost Bookmark

    George Lundberg, MD

    Cancer Network reports results from 5 years of follow up for a clinical trial in which the drug olaparib (Lynparza) was given to people who had already been treated for relapsed, high-grade serous, or endometrioid ovarian cancer—including primary peritoneal or fallopian tube cancer. Overall survival data show that olaparib outperformed a placebo drug for these patients, suggesting the possibility that it could be an effective “maintenance therapy.”

    .

  • August 15, 2020  

    Maintenance Avelumab Improves Survival in Advanced Bladder Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial for certain patients with advanced urothelial carcinoma, overall survival was prolonged by about 30% by using supportive care plus maintenance treatment with the drug avelumab, versus supportive care alone.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.